Tags: 
The first participant in a clinical safety trial for a COVID-19 vaccine conducted by the Kaiser Permanente Washington Health Research Institute in Seattle was given an experimental dose on March 16, reports the Associated Press. Testing will begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna INC.
Inovio pharmaceuticals will follow by starting tests of its vaccine in a dozen of volunteers next month.
These vaccines do not contain the virus, as such healthy volunteer participants have no chance to be infected.
Many other researchers, around the world, are working on many therapeutic options such as different type of vaccines, temporary vaccine and adoption of existing therapies.
Several approved drugs are tested in patients infected and/or sick with Covid19. Many of these drugs are not antiviral but able to reduce the massive inflammation reported in the patients in respiratory distress.
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.